{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:24:51Z","timestamp":1740122691314,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Scientific Research Projects Coordination Unit of Istanbul University","award":["TSA-2020-34930","TSA-2020-34930"],"award-info":[{"award-number":["TSA-2020-34930","TSA-2020-34930"]}]},{"name":"Istanbul University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A novel series of benzenesulfonamide substituted spirothiazolidinone derivatives (<jats:bold>3a\u2013j<\/jats:bold>) were synthesized, characterized and evaluated for their antiviral activity. The spirocyclic compounds were prepared by the condensation of 4-(aminosulfonyl)-2-methoxybenzohydrazide, appropriate cyclic ketones and 2-mercaptopropionic acid in a one-pot reaction. The structures of the new compounds were established by IR, <jats:sup>1<\/jats:sup>H NMR, <jats:sup>13<\/jats:sup>C NMR (APT), and elemental analysis. The new compounds were evaluated in vitro antiviral activity against influenza A\/H1N1, A\/H3N2 and B viruses, as well as herpes simplex virus type 1 (HSV-1), respiratory syncytial virus (RSV) and yellow fever virus (YFV). Two derivatives bearing propyl (<jats:bold>3d)<\/jats:bold> and <jats:italic>tert-<\/jats:italic>butyl (<jats:bold>3e)<\/jats:bold> substituents at position 8 of the spiro ring exhibited activity against influenza A\/H1N1 virus with EC50 values in the range of 35\u201345\u00a0\u00b5M and no cytotoxicity at 100\u00a0\u03bcM, the highest concentration tested.<\/jats:p>","DOI":"10.1007\/s11030-024-10912-x","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T05:01:51Z","timestamp":1719464511000},"page":"2681-2688","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["One-pot synthesis, characterization and antiviral properties of new benzenesulfonamide-based spirothiazolidinones"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6703-9389","authenticated-orcid":false,"given":"\u00c7a\u011fla Beg\u00fcm","family":"Apayd\u0131n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9742-9302","authenticated-orcid":false,"given":"Lieve","family":"Naesens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0516-6010","authenticated-orcid":false,"given":"G\u00f6k\u00e7e","family":"Cihan-\u00dcst\u00fcnda\u011f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"key":"10912_CR1","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S0140-6736(22)00982-5","volume":"400","author":"TM Uyeki","year":"2022","unstructured":"Uyeki TM, Hui DS, Zambon M, Wentworth DE, Monto AS (2022) Influenza. Lancet 400:693\u2013706. https:\/\/doi.org\/10.1016\/S0140-6736(22)00982-5","journal-title":"Lancet"},{"key":"10912_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-018-0002-y","volume":"4","author":"F Krammer","year":"2018","unstructured":"Krammer F, Smith GJD, Fouchier RAM, Peiris M, Kedzierska K, Doherty PC, Palese P, Shaw ML, Treanor J, Webster RG, Garcia-Sastre A (2018) Influenza. Nat Rev Dis Primers 4:3. https:\/\/doi.org\/10.1038\/s41572-018-0002-y","journal-title":"Nat Rev Dis Primers"},{"key":"10912_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrmicro.2017.118","volume":"16","author":"VN Petrova","year":"2018","unstructured":"Petrova VN, Russell CA (2018) The evolution of seasonal influenza viruses. Nat Rev Microbiol 16:47\u201360. https:\/\/doi.org\/10.1038\/nrmicro.2017.118","journal-title":"Nat Rev Microbiol"},{"key":"10912_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.tim.2019.08.010","volume":"28","author":"E de Vries","year":"2020","unstructured":"de Vries E, Du W, Guo H, de Haan CAM (2020) Influenza A virus hemagglutinin-neuraminidase-receptor balance: preserving virus motility. Trends Microbiol 28:57\u201367. https:\/\/doi.org\/10.1016\/j.tim.2019.08.010","journal-title":"Trends Microbiol"},{"key":"10912_CR5","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1056\/NEJMcp1512870","volume":"375","author":"JJ Treanor","year":"2016","unstructured":"Treanor JJ (2016) Clinical practice, influenza vaccination. N Engl J Med 375:1261\u20131268. https:\/\/doi.org\/10.1056\/NEJMcp1512870","journal-title":"N Engl J Med"},{"key":"10912_CR6","doi-asserted-by":"publisher","first-page":"a038463","DOI":"10.1101\/cshperspect.a038463","volume":"11","author":"JH Beigel","year":"2021","unstructured":"Beigel JH, Hayden FG (2021) Influenza therapeutics in clinical practice-challenges and recent advances. Cold Spring Harb Perspect Med 11:a038463. https:\/\/doi.org\/10.1101\/cshperspect.a038463","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10912_CR7","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/cid\/ciy866","volume":"68","author":"TM Uyeki","year":"2019","unstructured":"Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM, Fry AM, Gravenstein S, Hayden FG, Harper SA, Hirshon JM, Ison MG, Johnston BL, Knight SL, McGeer A, Riley LE, Wolfe CR, Alexander PE, Pavia AT (2019) Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis 68:895\u2013902. https:\/\/doi.org\/10.1093\/cid\/ciy866","journal-title":"Clin Infect Dis"},{"key":"10912_CR8","doi-asserted-by":"publisher","first-page":"105281","DOI":"10.1016\/j.antiviral.2022.105281","volume":"200","author":"EA Govorkova","year":"2022","unstructured":"Govorkova EA, Takashita E, Daniels RS, Fujisaki S, Presser LD, Patel MC, Huang W, Lackenby A, Nguyen HT, Pereyaslov D, Rattigan A, Brown SK, Samaan M, Subbarao K, Wong S, Wang D, Webby RJ, Yen HL, Zhang W, Meijer A, Gubareva LV (2022) Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018\u20132020. Antiviral Res 200:105281. https:\/\/doi.org\/10.1016\/j.antiviral.2022.105281","journal-title":"Antiviral Res"},{"key":"10912_CR9","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","volume":"100","author":"Y Furuta","year":"2013","unstructured":"Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL (2013) Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 100:446\u2013454. https:\/\/doi.org\/10.1016\/j.antiviral.2013.09.015","journal-title":"Antiviral Res"},{"key":"10912_CR10","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1093\/infdis\/jiac135","volume":"226","author":"FG Hayden","year":"2022","unstructured":"Hayden FG, Lenk RP, Stonis L, Oldham-Creamer C, Kang LL, Epstein C (2022) Favipiravir treatment of uncomplicated influenza in adults: results of two Phase 3, randomized, double-blind, placebo-controlled trials. J Infect Dis 226:1790\u20131799. https:\/\/doi.org\/10.1093\/infdis\/jiac135","journal-title":"J Infect Dis"},{"key":"10912_CR11","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/infdis\/jiz244","volume":"221","author":"T Uehara","year":"2020","unstructured":"Uehara T, Hayden FG, Kawaguchi K, Omoto S, Hurt AC, De Jong MD, Hirotsu N, Sugaya N, Lee N, Baba K, Shishido T, Tsuchiya K, Portsmouth S, Kida H (2020) Treatment-emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza. J Infect Dis 221:346\u2013355. https:\/\/doi.org\/10.1093\/infdis\/jiz244","journal-title":"J Infect Dis"},{"key":"10912_CR12","doi-asserted-by":"publisher","first-page":"101279","DOI":"10.1016\/j.coviro.2022.101279","volume":"57","author":"A Stevaert","year":"2022","unstructured":"Stevaert A, Groaz E, Naesens L (2022) Nucleoside analogs for management of respiratory virus infections: mechanism of action and clinical efficacy. Curr Opin Virol 57:101279","journal-title":"Curr Opin Virol"},{"key":"10912_CR13","first-page":"12575","volume":"13","author":"TA Ruzhentsova","year":"2021","unstructured":"Ruzhentsova TA, Oseshnyuk RA, Soluyanova TN, Dmitrikova EP, Mustafaev DM, Pokrovskiy KA, Markova TN, Rusanova MG, Kostina NE, Agafina AS, Brook YF, Bronov OY, Shults EI, Filon OV (2021) Phase 3 trial of coronavir (favipiravir) in patients with mild to moderate COVID-19. Am J Transl Res 13:12575\u201312587","journal-title":"Am J Transl Res"},{"key":"10912_CR14","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/jmv.25358","volume":"91","author":"IA Leneva","year":"2019","unstructured":"Leneva IA, Falynskova IN, Makhmudova NR, Poromov AA, Yatsyshina SB, Maleev VV (2019) Umifenovir susceptibility monitoring and characterization of influenza viruses isolated during ARBITR clinical study. J Med Virol 91:588\u2013597. https:\/\/doi.org\/10.1002\/jmv.25358","journal-title":"J Med Virol"},{"key":"10912_CR15","doi-asserted-by":"publisher","first-page":"e15874","DOI":"10.1371\/journal.pone.0015874","volume":"6","author":"E Teissier","year":"2011","unstructured":"Teissier E, Zandomeneghi G, Loquet A, Lavillette D, Lavergne JP, Montserret R, Cosset FL, Bockmann A, Meier BH, Penin F, Pecheur EI (2011) Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol. PLoS ONE 6:e15874. https:\/\/doi.org\/10.1371\/journal.pone.0015874","journal-title":"PLoS ONE"},{"key":"10912_CR16","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1073\/pnas.1617020114","volume":"114","author":"RU Kadam","year":"2017","unstructured":"Kadam RU, Wilson IA (2017) Structural basis of influenza virus fusion inhibition by the antiviral drug arbidol. Proc Natl Acad Sci USA 114:206\u2013214. https:\/\/doi.org\/10.1073\/pnas.1617020114","journal-title":"Proc Natl Acad Sci USA"},{"key":"10912_CR17","doi-asserted-by":"publisher","first-page":"997","DOI":"10.2174\/092986708784049658","volume":"15","author":"YS Boriskin","year":"2008","unstructured":"Boriskin YS, Leneva IA, Pecheur EI, Polyak SJ (2008) Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem 15:997\u20131005. https:\/\/doi.org\/10.2174\/092986708784049658","journal-title":"Curr Med Chem"},{"key":"10912_CR18","doi-asserted-by":"publisher","first-page":"115130","DOI":"10.1016\/j.bmc.2019.115130","volume":"28","author":"G Cihan-Ustundag","year":"2020","unstructured":"Cihan-Ustundag G, Zopun M, Vanderlinden E, Ozkirimli E, Persoons L, Capan G, Naesens L (2020) Superior inhibition of influenza virus hemagglutinin-mediated fusion by indole-substituted spirothiazolidinones. Bioorg Med Chem 28:115130. https:\/\/doi.org\/10.1016\/j.bmc.2019.115130","journal-title":"Bioorg Med Chem"},{"key":"10912_CR19","doi-asserted-by":"publisher","first-page":"a038638","DOI":"10.1101\/cshperspect.a038638","volume":"11","author":"SJ Gamblin","year":"2020","unstructured":"Gamblin SJ, Vachieri SG, Xiong X, Zhang J, Martin SR, Skehel JJ (2020) Hemagglutinin structure and activities. Cold Spring Harb Perspect Med 11:a038638. https:\/\/doi.org\/10.1101\/cshperspect.a038638","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10912_CR20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/med.21289","volume":"34","author":"E Vanderlinden","year":"2014","unstructured":"Vanderlinden E, Naesens L (2014) Emerging antiviral strategies to interfere with influenza virus entry. Med Res Rev 34:301\u2013339. https:\/\/doi.org\/10.1002\/med.21289","journal-title":"Med Res Rev"},{"key":"10912_CR21","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3390\/ph14060587","volume":"14","author":"Z Chen","year":"2021","unstructured":"Chen Z, Cui Q, Caffrey M, Rong L, Du R (2021) Small molecule inhibitors of influenza virus entry. Pharmaceuticals (Basel) 14:587. https:\/\/doi.org\/10.3390\/ph14060587","journal-title":"Pharmaceuticals (Basel)"},{"key":"10912_CR22","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1126\/science.aar6221","volume":"363","author":"MJP van Dongen","year":"2019","unstructured":"van Dongen MJP, Kadam RU, Juraszek J, Lawson E, Brandenburg B, Schmitz F, Schepens WBG, Stoops B, van Diepen HA, Jongeneelen M, Tang C, Vermond J, van Eijgen-Obregoso RA, Blokland S, Garg D, Yu W, Goutier W, Lanckacker E, Klap JM, Peeters DCG, Wu J, Buyck C, Jonckers THM, Roymans D, Roevens P, Vogels R, Koudstaal W, Friesen RHE, Raboisson P, Dhanak D, Goudsmit J, Wilson IA (2019) A small-molecule fusion inhibitor of influenza virus is orally active in mice. Science 363:1056. https:\/\/doi.org\/10.1126\/science.aar6221","journal-title":"Science"},{"key":"10912_CR23","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1128\/JVI.02325-09","volume":"84","author":"E Vanderlinden","year":"2010","unstructured":"Vanderlinden E, G\u00f6ktas F, Cesur Z, Froeyen M, Reed ML, Russell CJ, Cesur N, Naesens L (2010) Novel inhibitors of influenza virus fusion: structure-activity relationship and interaction with the viral hemagglutinin. J Virol 84:4277\u20134288. https:\/\/doi.org\/10.1128\/JVI.02325-09","journal-title":"J Virol"},{"key":"10912_CR24","doi-asserted-by":"publisher","first-page":"7155","DOI":"10.1016\/j.bmc.2012.09.064","volume":"20","author":"F Goktas","year":"2012","unstructured":"Goktas F, Vanderlinden E, Naesens L, Cesur N, Cesur Z (2012) Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives. Bioorg Med Chem 20:7155\u20137159. https:\/\/doi.org\/10.1016\/j.bmc.2012.09.064","journal-title":"Bioorg Med Chem"},{"key":"10912_CR25","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1080\/10426507.2014.965819","volume":"190","author":"F Goktas","year":"2015","unstructured":"Goktas F, Vanderlinden E, Naesens L, Cesur Z, Cesur N, Tas P (2015) Synthesis and structure-activity relationship of N-(3-oxo-1-thia-4-azaspiro[4.5] decan-4-yl)carboxamide inhibitors of influenza virus hemagglutinin mediated fusion. Phosphorus Sulfur Silicon Relat Elem 190:1075\u20131087. https:\/\/doi.org\/10.1080\/10426507.2014.965819","journal-title":"Phosphorus Sulfur Silicon Relat Elem"},{"key":"10912_CR26","doi-asserted-by":"publisher","first-page":"e1900028","DOI":"10.1002\/ardp.201900028","volume":"352","author":"F Goktas","year":"2019","unstructured":"Goktas F, Ozbil M, Cesur N, Vanderlinden E, Naesens L, Cesur Z (2019) Novel N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives as potent and selective influenza virus fusion inhibitors. Arch Pharm (Weinheim) 352:e1900028. https:\/\/doi.org\/10.1002\/ardp.201900028","journal-title":"Arch Pharm (Weinheim)"},{"key":"10912_CR27","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1080\/10426507.2020.1828886","volume":"196","author":"\u00c7B Apayd\u0131n","year":"2020","unstructured":"Apayd\u0131n \u00c7B, Van Loy B, Stevaert A, Naesens L (2020) New spirothiazolidinone derivatives: synthesis and antiviral evaluation. Phosphorus Sulfur Silicon Relat Elem 196:294\u2013299. https:\/\/doi.org\/10.1080\/10426507.2020.1828886","journal-title":"Phosphorus Sulfur Silicon Relat Elem"},{"key":"10912_CR28","doi-asserted-by":"publisher","first-page":"104958","DOI":"10.1016\/j.bioorg.2021.104958","volume":"112","author":"\u00c7B Apayd\u0131n","year":"2021","unstructured":"Apayd\u0131n \u00c7B, Tansuyu M, Cesur Z, Naesens L, G\u00f6kta\u015f F (2021) Design, synthesis and anti-influenza virus activity of furan-substituted spirothiazolidinones. Bioorg Chem 112:104958. https:\/\/doi.org\/10.1016\/j.bioorg.2021.104958","journal-title":"Bioorg Chem"},{"key":"10912_CR29","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/med.10047","volume":"23","author":"C Supuran","year":"2003","unstructured":"Supuran C, Casini A, Scozzafava A (2003) Protease inhibitors of the sulfonamidetype: anticancer anticancer, antiinlammatory, and antiviral agents. Med Res Rev 23:535\u2013558. https:\/\/doi.org\/10.1002\/med.10047","journal-title":"Med Res Rev"},{"key":"10912_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules28010051","volume":"28","author":"M Moskalik","year":"2023","unstructured":"Moskalik M (2023) Sulfonamides with heterocyclic periphery as antiviral agents. Molecules 28:1\u201315. https:\/\/doi.org\/10.3390\/molecules28010051","journal-title":"Molecules"},{"issue":"7","key":"10912_CR31","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1055\/s-0031-1299931","volume":"52","author":"N Ulusoy","year":"2002","unstructured":"Ulusoy N (2002) Synthesis and antituberculosis activity of cycloalkylidenehydrazide and 4-aza-1-thiaspiro[4.5]decan-3-one derivatives of imidazo[2,1-b]thiazole. Arzneimittelforschung 52(7):565\u2013571. https:\/\/doi.org\/10.1055\/s-0031-1299931","journal-title":"Arzneimittelforschung"},{"issue":"3","key":"10912_CR32","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s11030-012-9385-y","volume":"16","author":"G Cihan-\u00dcst\u00fcnda\u011f","year":"2012","unstructured":"Cihan-\u00dcst\u00fcnda\u011f G, Capan G (2012) Synthesis and evaluation of functionalized indoles as antimycobacterial and anticancer agents. Mol Divers 16(3):525\u2013539. https:\/\/doi.org\/10.1007\/s11030-012-9385-y","journal-title":"Mol Divers"},{"key":"10912_CR33","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1099\/jgv.0.001235","volume":"100","author":"P Vrijens","year":"2019","unstructured":"Vrijens P, Noppen S, Boogaerts T, Vanstreels E, Ronca R, Chiodelli P, Laporte M, Vanderlinden E, Liekens S, Stevaert A, Naesens L (2019) Influenza virus entry via the GM3 ganglioside-mediated platelet-derived growth factor receptor beta signalling pathway. J Gen Virol 100:583\u2013601. https:\/\/doi.org\/10.1099\/jgv.0.001235","journal-title":"J Gen Virol"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-10912-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-024-10912-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-10912-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T04:10:05Z","timestamp":1728015005000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-024-10912-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10912"],"URL":"https:\/\/doi.org\/10.1007\/s11030-024-10912-x","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"type":"print","value":"1381-1991"},{"type":"electronic","value":"1573-501X"}],"subject":[],"published":{"date-parts":[[2024,6,27]]},"assertion":[{"value":"25 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}